Prognostic Association of the Two-Cycle On-Treatment CRAFITY Score in Advanced HCC: A Single-Center Retrospective Cohort Study.
- 1Department of Hepatobiliary Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361015, China.
- 2Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361015, China.
- 3Fujian Provincial Clinical Research Center for Precision Medicine of Abdominal Tumors, Xiamen 361015, China.
Abstract
The baseline CRAFITY score, derived from AFP and C-reactive protein, is a validated prognostic biomarker for hepatocellular carcinoma (HCC) patients receiving immunotherapy. However, whether its prognostic value can be improved by on-treatment reassessment remains unclear. We evaluated the two-cycle on-treatment CRAFITY score in 108 advanced-HCC patients who received immune-based combination therapy as first- or second-line treatment. The score was calculated at baseline and after two cycles. Kaplan-Meier, Cox regression, time-dependent ROC, landmark, and sensitivity analyses were performed. The two-cycle score significantly stratified overall survival (median OS from landmark: 34.6, 12.9, and 6.7 months for scores 0, 1, and 2; p < 0.0001) and remained independently associated with OS after adjustment for vascular invasion, treatment line, and concomitant transarterial chemoembolization (TACE) (HR 2.36, 95% CI 1.70-3.29, p < 0.001). The baseline score showed only borderline associations (OS p = 0.07; PFS p = 0.09). The two-cycle score had an apparent AUC of 0.709 (95% CI 0.586-0.832) at 6 months and 0.745 (95% CI 0.658-0.832) at 12 months. The corresponding values for the baseline score were 0.645 and 0.638. Adding the two-cycle score to a clinical reference model increased the 12-month AUC from 0.699 to 0.811 (ΔAUC = 0.112). Bootstrap internal validation yielded an optimism-corrected C-index of 0.698 (95% CI 0.650-0.776). In conclusion, the two-cycle CRAFITY score provides complementary posttreatment prognostic information for early risk stratification, but prospective external validation is required before clinical application.
Related
- Treatment-Free Interval as a Prognostic Factor for Survival Outcomes in Patients with Advanced or Recurrent Endometrial Cancer Treated with Pembrolizumab Plus Lenvatinib: A Multi-Institutional Real-World Cohort Study
- Association Between the Naples Prognostic Score and In-Hospital Mortality in Patients with Type 2 Cardiorenal Syndrome: A Retrospective Cohort Study
- Treatment patterns and prognostic factors of radiation-associated esophageal fistula in patients with esophageal squamous cell carcinoma: a retrospective cohort study
- Association of Complete Metabolic Response on Post-Neoadjuvant 18F-FDG PET/CT with Complete Cytoreduction in Advanced High-Grade Serous Tubo-Ovarian Carcinoma: A Retrospective Single-Center Cohort Study
- Treatment Outcomes and Prognostic Factors in Children with Myeloid Leukemia Associated with Down Syndrome: A Nationwide Polish Retrospective Study
BibTeX
@article{chen2026prognostic,
title = {{Prognostic Association of the Two-Cycle On-Treatment CRAFITY Score in Advanced HCC: A Single-Center Retrospective Cohort Study.}},
author = {Xiaochun Chen and Xinkun Guo and Guobin Chen and Susu Zheng and Yanfang Wu and Jingfang Wu and Hong Chen and Zhenzhen Zhang and Boheng Zhang},
journal = {Current oncology (Toronto, Ont.)},
year = {2026},
month = oct,
doi = {10.3390/curroncol33100598},
url = {https://europepmc.org/article/MED/42930165},
note = {CC BY},
}
RIS
TY - JOUR
TI - Prognostic Association of the Two-Cycle On-Treatment CRAFITY Score in Advanced HCC: A Single-Center Retrospective Cohort Study.
AU - Xiaochun Chen
AU - Xinkun Guo
AU - Guobin Chen
AU - Susu Zheng
AU - Yanfang Wu
AU - Jingfang Wu
AU - Hong Chen
AU - Zhenzhen Zhang
AU - Boheng Zhang
PY - 2026
DA - 2026/10/02
JO - Current oncology (Toronto, Ont.)
DO - 10.3390/curroncol33100598
UR - https://europepmc.org/article/MED/42930165
AB - The baseline CRAFITY score, derived from AFP and C-reactive protein, is a validated prognostic biomarker for hepatocellular carcinoma (HCC) patients receiving immunotherapy. However, whether its prognostic value can be improved by on-treatment reassessment remains unclear. We evaluated the two-cycle on-treatment CRAFITY score in 108 advanced-HCC patients who received immune-based combination therapy as first- or second-line treatment. The score was calculated at baseline and after two cycles. Kaplan-Meier, Cox regression, time-dependent ROC, landmark, and sensitivity analyses were performed. The two-cycle score significantly stratified overall survival (median OS from landmark: 34.6, 12.9, and 6.7 months for scores 0, 1, and 2; p < 0.0001) and remained independently associated with OS after adjustment for vascular invasion, treatment line, and concomitant transarterial chemoembolization (TACE) (HR 2.36, 95% CI 1.70-3.29, p < 0.001). The baseline score showed only borderline associations (OS p = 0.07; PFS p = 0.09). The two-cycle score had an apparent AUC of 0.709 (95% CI 0.586-0.832) at 6 months and 0.745 (95% CI 0.658-0.832) at 12 months. The corresponding values for the baseline score were 0.645 and 0.638. Adding the two-cycle score to a clinical reference model increased the 12-month AUC from 0.699 to 0.811 (ΔAUC = 0.112). Bootstrap internal validation yielded an optimism-corrected C-index of 0.698 (95% CI 0.650-0.776). In conclusion, the two-cycle CRAFITY score provides complementary posttreatment prognostic information for early risk stratification, but prospective external validation is required before clinical application.
SN - 1198-0052
SN - 1718-7729
ER -